checkAd

     114  0 Kommentare Great Elm Capital Group, Inc. Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results

    • DME fiscal Q4 revenue grew 7.9% year-over-year despite a significant negative impact from COVID-19

    • DME fiscal Q4 net income of $2.8 million and adjusted EBITDA of $7.0 million, up from ($1.0) million and $2.8 million, respectively, during the same period in the prior year
    • Investment Management is poised for growth in AUM, revenue, and earnings if GECC rights offering is completed
    • Consolidated fiscal Q4 net income of $4.1 million, up from ($1.0) million during the same period in the prior year

    WALTHAM, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) --  Great Elm Capital Group, Inc. (NASDAQ: GEC, “Great Elm”) announced its financial results for the fiscal quarter and year ended June 30, 2020. Great Elm will host a conference call and webcast on Friday, September 18, 2020 at 8:00 a.m. Eastern Time to discuss its fiscal fourth quarter 2020 financial results. Please see below for details.

    BUSINESS OVERVIEW

    Great Elm is a diversified, publicly-traded holding company that seeks to build long-term shareholder value across two verticals: Operating Companies and Investment Management.

    Select highlights from the fiscal fourth quarter 2020 include:

    • Operating Companies:
      • DME’s investments in people, process and technology have been critical in adapting to uncertain business conditions caused by the COVID-19 pandemic. DME continues to operate and serve patients in all markets
      • Having completed significant investments into the platform, DME management is focused on continuing organic growth, driving improved margins, and making add-on acquisitions
      • During the quarter ended June 30, 2020, physician referrals declined in response to shelter-in-place orders. This resulted in new PAP patient setups declining 23% year-over-year. Throughout the quarter, both physician referrals and PAP setups improved over their post-COVID lows, but have not yet reached pre-COVID levels.
      • For the three months ended June 30, 2020, generated $13.9 million of revenue, $2.8 million of net income and $7.0 million of adjusted EBITDA
    • Investment Management:
      • For the three months ended June 30, 2020, generated $0.8 million of revenue, net income of ($0.0) million and $0.2 million of adjusted EBITDA
      • Great Elm Capital Corp. (“GECC”) managed by Great Elm Capital Management, Inc. (“GECM”), announced a rights offering on August 31, 2020. If completed, this would increase AUM, revenue, and earnings for our Investment Management business
      • Great Elm and certain other shareholders of GECC (the “Participating Shareholders”) have agreed to purchase up to $24 million of shares in this offering through an exercise of their basic and oversubscription rights; provided that any over-subscription by the Participating Shareholders will be effected only after pro rata allocation of over-subscription shares to record date holders (other than the Participating Shareholders) who fully exercise all rights issued to them

    “We have significant momentum in both our DME business and our Investment Management business,” remarked Peter A. Reed, Great Elm’s Chief Executive Officer. “After a long period of investment in the platform, DME is focused on driving organic growth and making follow on acquisitions. GECC has had success in its specialty finance investments, has an attractive pipeline of potential future investments, and has announced a rights offering in order to capitalize upon those opportunities.”

    Alignment of Interest

    The employees of Great Elm and GECM collectively own approximately 2.0 million shares of GEC stock, representing approximately 7% of its outstanding shares. Additionally, the directors of Great Elm collectively own or manage approximately 20% of Great Elm’s shares. Altogether, insiders collectively own or manage approximately 27% of the company’s outstanding shares, which Great Elm believes fosters a strong alignment of interest between employees, directors and the company’s shareholders.

    Operating Companies

    In the three months ended June 30, 2020, DME generated $2.8 million of net income and $7.0 million of adjusted EBITDA, an increase from ($1.0) million of net income and $2.8 million of adjusted EBITDA during the same period in the prior year. During the quarter, DME experienced significant growth in its sales of PAP supplies, with more moderate growth in rental revenue driven by lower new PAP patient setups. We continue to explore ways to lower DME’s cost of capital and obtain additional funds for potential future acquisitions.

    Investment Management

    In the three months ended June 30, 2020, Investment Management generated ($0.0) million of net income and $0.2 million of adjusted EBITDA1, an increase from ($0.1) million of net income and $0.0 million of adjusted EBITDA during the same period in the prior year. We remain focused on driving increased revenue and earnings through higher AUM. During the quarter, GECC benefitted from strong performance of its specialty finance investments, the redeployment of funds into attractive risk-adjusted opportunities and the rebounding of the valuations of certain of its investments following COVID related volatility in the prior quarter.

    FINANCIAL REVIEW: SEGMENT FINANCIALS

    As of June 30, 2020, Great Elm had four operating segments: Durable Medical Equipment, Investment Management, Real Estate and General Corporate.

    Durable Medical Equipment

    Three and Twelve Months Ended June 30, 2020:2

    Revenue:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $13.9 million and $55.7 million in total revenue vs. $12.9 million and $41.9 million during the same periods in the prior year.

    Net Income (Loss):

    • During the three and twelve months ended June 30, 2020, Great Elm recognized net income of $2.8 million and a net loss of $0.1 million vs. a net loss of $1.0 million and $1.1 million during the same periods in the prior year.

    Adjusted EBITDA:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $7.0 million and $16.0 million of adjusted EBITDA vs. $2.8 million and $10.4 million during the same periods in the prior year.

    1Prior year non-GAAP adjustments have been updated to conform to current year presentation by removing adjustments associated with the adoption of ASC 606 Contracts with Customers
    2 Prior year twelve-month period reflects a partial year from September 7, 2018 to June 30, 2019

    Investment Management

    Three and Twelve Months Ended June 30, 2020:

    Revenue:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized total investment management revenue of $0.7 million and $3.3 million vs. $0.9 million and $3.8 million during the same periods in the prior year.

    Net Income (Loss):

    • During the three and twelve months ended June 30, 2020, Great Elm recognized net income of ($0.0) million and $0.4 million vs. a net loss of $0.1 million and $1.0 million during the same periods in the prior year.

    Adjusted EBITDA1:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized adjusted EBITDA of $0.2 million and $1.2 million vs. $0.0 million and $0.4 million during the same periods in the prior year.

    Real Estate

    Three and Twelve Months Ended June 30, 2020:

    Revenue:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $1.3 million and $5.1 million in rental revenue vs. $1.3 million and $5.5 million during the same periods in the prior year.

    Net Income (Loss):

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $0.03 million and $0.2 million in net income vs. $0.06 million and $0.2 million in net income during the same periods in the prior year.

    Adjusted EBITDA:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $1.1 million and $4.6 million in adjusted EBITDA vs. $1.2 million and $4.6 million during the same periods in the prior year.

    General Corporate

    Three and Twelve Months Ended June 30, 2020:

    Revenue:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $0.05 million and $.16 million in revenue vs. approximately $0.06 million and $.12 million in revenue during the same periods in the prior year.

    Net Income (Loss):

    • During the three and twelve months ended June 30, 2020, Great Elm recognized $1.3 million in net income and a net loss of $13.7 million vs. $0.04 million in net income and a net loss of $1.2 million during the same periods in the prior year. $2.9 million of the $1.3 million net income during the quarter derived from an unrealized gain on our investment in GECC stock

    Adjusted EBITDA:

    • During the three and twelve months ended June 30, 2020, Great Elm recognized ($1.2) million and ($6.0) million in adjusted EBITDA vs. ($1.6) million and ($6.1) million during the same periods in the prior year.

    Conference Call & Webcast 

    Great Elm will host a conference call and webcast on Friday, September 18, 2020 at 8:00 a.m. Eastern Time to discuss its fiscal fourth quarter 2020 financial results.  

    All interested parties are invited to participate in the conference call by dialing +1 (844) 559-0750; international callers should dial +1 (647) 689-5386. Participants should enter the Conference ID 2416529 when asked. For a copy of the slide presentation that will be referenced during the course of our conference call, please visit: https://www.greatelmcap.com/events-and-presentations/default.aspx.  

    The conference call will be webcast simultaneously at: https://event.on24.com/wcc/r/2395114/5E5DD7BDBB644C6852EF57E7C8AA0EE5

    About Great Elm Capital Group, Inc.

    Great Elm is a publicly-traded holding company that seeks to build a business across two operating verticals: Operating Companies and Investment Management. Great Elm’s website can be found at www.greatelmcap.com.

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

    Statements in this press release that are “forward-looking” statements, including statements regarding expected growth, profitability and outlook involve risks and uncertainties that may individually or collectively impact the matters described herein. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and represent Great Elm’s assumptions and expectations in light of currently available information. These statements involve risks, variables and uncertainties, and Great Elm’s actual performance results may differ from those projected, and any such differences may be material. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are risks associated with the economic impact of the COVID-19 pandemic on Great Elm’s businesses, including DME as well as GECC and its portfolio investments. For information on certain factors that could cause actual events or results to differ materially from Great Elm’s expectations, please see Great Elm’s filings with the SEC, including its most recent annual report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Additional information relating to Great Elm’s financial position and results of operations is also contained in Great Elm’s annual and quarterly reports filed with the SEC and available for download at its website www.greatelmcap.com or at the SEC website www.sec.gov.

    Non-GAAP Financial Measures

    The SEC has adopted rules to regulate the use in filings with the SEC, and in public disclosures, of financial measures that are not in accordance with US GAAP, such as adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”). Adjusted EBITDA is derived from methodologies other than in accordance with US GAAP. Great Elm believes that Adjusted EBITDA is an important measure for investors to use in evaluating Great Elm’s businesses. In addition, Great Elm’s management reviews Adjusted EBITDA as they evaluate acquisition opportunities.

    Adjusted EBITDA has limitations as an analytical tool, and you should not consider it either in isolation from, or as a substitute for, analyzing Great Elm’s results as reported under US GAAP. Non-GAAP financial measures reported by Great Elm may not be comparable to similarly titled amounts reported by other companies.

    Set forth below is a reconciliation of Adjusted EBITDA to the most directly comparable US GAAP financial measure, net income. The information in the table below represents Great Elm’s assumptions and expectations in light of currently available information. Great Elm’s actual performance results may differ from those projected in in the table below, and any such differences may be material.

                         
        For the three months ended June 30, 2020
    $ in thousands   Durable Medical
    Equipment
    (1)
      Investment
    Management
    (2)
      Real Estate   General
    Corporate
      Consolidated
    EBITDA:                    
    Net income (loss) - GAAP   $ 2,787     $ (15 )   $ 33   $ 1,291     $ 4,096  
    Interest expense     816       35       652     609       2,112  
    Depreciation & Amortization     2,800       127       430     1       3,358  
    Tax expense     -       -       -     49       49  
    EBITDA   $ 6,403     $ 147     $ 1,115   $ 1,950     $ 9,615  
    Adjusted EBITDA                    
    Stock based compensation     -       67       -     246       313  
    GECC dividend income     -       -       -     (500 )     (500 )
    GECC Unrealized (gains) / losses     -       -       -     (2,919 )     (2,919 )
    Other (income) expense     (2 )     -       -     -       (2 )
    Transaction and integration costs (3)     417       -       -     36       453  
    Severance     53       -       -     -       53  
    Location start up expense     9       -       -     -       9  
    DME management and monitoring fees     70       -       -     (45 )     25  
    Adjusted EBITDA   $ 6,950     $ 214     $ 1,115   $ (1,232 )   $ 7,047  
                         


        For the year ended June 30, 2020
    $ in thousands   Durable Medical
    Equipment
    (1)
      Investment
    Management
    (2)
      Real Estate   General
    Corporate
      Consolidated
    EBITDA:                    
    Net income (loss) - GAAP   $ (106 )   $ 435     $ 219   $ (13,675 )   $ (13,127 )
    Interest expense     3,655       157       2,619     764       7,195  
    Depreciation & Amortization     10,145       636       1,722     1       12,504  
    Tax expense     -       -       -     44       44  
    EBITDA   $ 13,694     $ 1,228     $ 4,560   $ (12,866 )   $ 6,616  
    Adjusted EBITDA                    
    Stock based compensation     -       (33 )     -     580       547  
    Change in contingent consideration (3)     -       -       -     (1,135 )     (1,135 )
    GECC dividend income     -       -       -     (2,067 )     (2,067 )
    GECC Unrealized (gains) / losses     -       -       -     8,684       8,684  
    Other (income) expense     (5 )     -       -     -       (5 )
    Transaction and integration costs (3)     1,693       -       -     962       2,655  
    Severance     53       -       -     -       53  
    Location start up expense     329       -       -     -       329  
    DME management and monitoring fees     259       -       -     (159 )     100  
    Adjusted EBITDA   $ 16,023     $ 1,195     $ 4,560   $ (6,002 )   $ 15,777  
                         


                         
        For the three months ended June 30, 2019
    $ in thousands   Durable Medical
    Equipment
    (1)
      Investment
    Management
    (2)
      Real
     Estate
      General
    Corporate
      Consolidated
    EBITDA:                    
    Net income (loss) - GAAP   $ (1,016 )   $ (136 )   $ 64   $ 41     $ (1,047 )
    Net income from discontinued operations - GAAP     -       -       -     50       50  
    Interest expense     1,050       45       660     -       1,755  
    Depreciation & Amortization     2,033       178       431     -       2,640  
    Tax expense     -       -       -     (953 )     (953 )
    EBITDA   $ 2,067     $ 87     $ 1,155   $ (862 )   $ 2,447  
    Adjusted EBITDA                    
    Stock based compensation     -       (80 )     -     114       34  
    GECC dividend income     (88 )     -       -     (402 )     (490 )
    GECC Unrealized (gains) / losses     (116 )     -       -     (749 )     (865 )
    Transaction and integration costs (3)     218       -       -     401       619  
    Severance     8       -       -     3       11  
    Location start up expense     103       -       -     -       103  
    Changes in revenue reserve estimates related to system conversions (4)     231       -       -     -       231  
    Equipment sold outside of predominant use (4)     354       -       -     -       354  
    Finalization of purchase accounting valuations (4)     (43 )     -       -     -       (43 )
    DME management and monitoring fees     94       -       -     (69 )     25  
    Adjusted EBITDA   $ 2,828     $ 7     $ 1,155   $ (1,564 )   $ 2,426  
                         


        For the year ended June 30, 2019
    (Dollar amounts in thousands)   Durable Medical
    Equipment
    (1)
      Investment
    Management
    (2)
      Real Estate   General
    Corporate
      Consolidated
    EBITDA:                    
    Net income (loss) - GAAP   $ (1,107 )   $ (995 )   $ 191   $ (1,221 )   $ (3,132 )
    Net income from discontinued operations - GAAP     -       -       -     (3,736 )     (3,736 )
    Interest expense     3,415       180       2,655     -       6,250  
    Depreciation & Amortization     6,873       631       1,729     -       9,233  
    Tax expense     -       -       -     (2,182 )     (2,182 )
    EBITDA   $ 9,181     $ (184 )   $ 4,575   $ (7,139 )   $ 6,433  
    Adjusted EBITDA:                    
    Stock based compensation     -       521       -     457       978  
    Change in contingent consideration (3)     -       -       -     469       469  
    Dividend income from GECC     (717 )     -       -     (1,714 )     (2,431 )
    Unrealized (gain) loss on investment in GECC     894       -       -     168       1,062  
    Severance costs     8       46       -     209       263  
    Location start up expense     161       -       -     -       161  
    DME management and monitoring fees     217       -       -     (134 )     83  
    Finalization of purchase accounting valuations (4)     (143 )     -       -     -       (143 )
    Transaction and integration costs (3)     769       -       -     1,582       2,351  
    Adjusted EBITDA   $ 10,370     $ 383     $ 4,575   $ (6,102 )   $ 9,226  
                         

    (1): Our durable medical equipment business began in September 2018.  Prior year figures represent activity for the period September 1, 2018 through June 30, 2019, where applicable.

    (2): Prior year non-GAAP adjustments have been updated to conform to current year presentation by removing adjustments associated with the adoption of ASC 606 Contracts with Customers.

    (3): Transaction and integration related costs include costs to acquire and integrate acquired businesses.  This also represents change in contingent consideration liability since the initial valuation at the acquisition date.

    (4): Represents approximately $0.5 million of aggregate adjustments which negatively impact adjusted EBITDA by the same amount for the period beginning with the acquisition of DME on September 7, 2018 and ending March 31, 2019. There is no material impact on the US GAAP numbers reported for this period.

    Media & Investor Contact:
    Investor Relations
    +1 (617) 375-3006
    investorrelations@greatelmcap.com





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Great Elm Capital Group, Inc. Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results DME fiscal Q4 revenue grew 7.9% year-over-year despite a significant negative impact from COVID-19DME fiscal Q4 net income of $2.8 million and adjusted EBITDA of $7.0 million, up from ($1.0) million and $2.8 million, respectively, during the same …